Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy and precision oncology treatment options may improve patient outcomes. Next-generation sequencing (NGS) is an established tool that enables multigene panel analysis. Methods: This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021. Results: A targetable lesion was detected in 15.6% of patients. BRCA1/2 mutations were identified in 16 patients, of whom 13 had germline mutations; 8 of these patients received olaparib. In 41.4% of patients, homologous recombination repair genes were affected. Two cases of ATP1B1-NRG1 fusions and seven cases of dMMR tumors were found, leading to individualized treatment. KRAS mutations were present in 70.3%, and TP53 mutations were present in 63.3%. A total of 80.5% of patients received platinum-based chemotherapy, predominantly FOLFIRINOX. Conclusion: The high frequency of targetable alterations in our cohort underscores upfront NGS testing in PDAC. Younger patients, those with a positive family history, and KRAS WT patients should be of particular interest.
Journal Section:
Research Article
References
1.
Rahib
L
, Smith
BD
, Aizenberg
R
, Rosenzweig
AB
, Fleshman
JM
, Matrisian
LM
. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States
. Cancer Res
. 2014
;74
(11
):2913
–21
. 2.
Stoop
TF
, Theijse
RT
, Seelen
LWF
, Groot Koerkamp
B
, van Eijck
CHJ
, Wolfgang
CL
, et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
. Nat Rev Gastroenterol Hepatol
. 2024
;21
(2
):101
–24
. 3.
Cronin
KA
, Scott
S
, Firth
AU
, Sung
H
, Henley
SJ
, Sherman
RL
, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics
. Cancer
. 2022
;128
(24
):4251
–84
. 4.
Rawla
P
, Sunkara
T
, Gaduputi
V
. Epidemiology of pancreatic cancer: global trends, etiology and risk factors
. World J Oncol
. 2019
;10
(1
):10
–27
. 5.
Alsop
K
, Fereday
S
, Meldrum
C
, deFazio
A
, Emmanuel
C
, George
J
, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group
. J Clin Oncol
. 2012
;30
(21
):2654
–63
. 6.
Waddell
N
, Pajic
M
, Patch
AM
, Chang
DK
, Kassahn
KS
, Bailey
P
, et al. Whole genomes redefine the mutational landscape of pancreatic cancer
. Nature
. 2015
;518
(7540
):495
–501
. 7.
Holter
S
, Borgida
A
, Dodd
A
, Grant
R
, Semotiuk
K
, Hedley
D
, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma
. J Clin Oncol
. 2015
;33
(28
):3124
–9
. 8.
Lowery
MA
, Wong
W
, Jordan
EJ
, Lee
JW
, Kemel
Y
, Vijai
J
, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms
. J Natl Cancer Inst
. 2018
;110
(10
):1067
–74
. 9.
O’Reilly
EM
, Lee
JW
, Zalupski
M
, Capanu
M
, Park
J
, Golan
T
, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation
. J Clin Oncol
. 2020
;38
(13
):1378
–88
.10.
Grant
TJ
, Hua
K
, Singh
A
. Molecular pathogenesis of pancreatic cancer
. Prog Mol Biol Transl Sci
. 2016
;144
:241
–75
. 11.
Jiang
S
, Fagman
JB
, Ma
Y
, Liu
J
, Vihav
C
, Engstrom
C
, et al. A comprehensive review of pancreatic cancer and its therapeutic challenges
. Aging (Albany NY)
. 2022
;14
(18
):7635
–49
. 12.
Strickler
JH
, Satake
H
, George
TJ
, Yaeger
R
, Hollebecque
A
, Garrido-Laguna
I
, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer
. N Engl J Med
. 2023
;388
(1
):33
–43
. 13.
Marabelle
A
, Le
DT
, Ascierto
PA
, Di Giacomo
AM
, De Jesus-Acosta
A
, Delord
JP
, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study
. J Clin Oncol
. 2020
;38
(1
):1
–10
. 14.
Taïeb
J
, Sayah
L
, Heinrich
K
, Kunzmann
V
, Boileve
A
, Cirkel
G
, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
. Eur J Cancer
. 2023
;188
:90
–7
. 15.
Golan
T
, Hammel
P
, Reni
M
, Van Cutsem
E
, Macarulla
T
, Hall
MJ
, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer
. N Engl J Med
. 2019
;381
(4
):317
–27
. 16.
Robert Koch-Institut
. Falldefinitionen des Robert Koch-Instituts zur Übermittlung von Erkrankungs- oder Todesfällen und Nachweisen von Krankheitserregern. Ausgabe 2017/18
. Robert Koch-Institut
; 2021
.17.
Shindo
K
, Yu
J
, Suenaga
M
, Fesharakizadeh
S
, Cho
C
, Macgregor-Das
A
, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma
. J Clin Oncol
. 2017
;35
(30
):3382
–90
. 18.
Stoffel
EM
, McKernin
SE
, Brand
R
, Canto
M
, Goggins
M
, Moravek
C
, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion
. J Clin Oncol
. 2019
;37
(2
):153
–64
. 19.
Sohal
DPS
, Kennedy
EB
, Cinar
P
, Conroy
T
, Copur
MS
, Crane
CH
, et al. Metastatic pancreatic cancer: ASCO guideline update
. J Clin Oncol
. 2020
;38
(27
):3217
–30
. 20.
Singh
H
, Keller
RB
, Kapner
KS
, Dilly
J
, Raghavan
S
, Yuan
C
, et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
. Clin Cancer Res
. 2023
;29
(22
):4627
–43
. 21.
Yousef
A
, Yousef
M
, Chowdhury
S
, Abdilleh
K
, Knafl
M
, Edelkamp
P
, et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
. NPJ Precis Oncol
. 2024
;8
(1
):27
. 22.
Reissig
TM
, Tzianopoulos
I
, Liffers
ST
, Rosery
VK
, Guyot
M
, Ting
S
, et al. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer
. ESMO Open
. 2023
;8
(3
):101539
. 23.
Malvi
D
, Vasuri
F
, Maloberti
T
, Sanza
V
, De Leo
A
, Fornelli
A
, et al. Molecular characterization of pancreatic ductal adenocarcinoma using a next-generation sequencing custom-designed multigene panel
. Diagnostics
. 2022
;12
(5
):1058
. 24.
Luo
J
. KRAS mutation in pancreatic cancer
. Semin Oncol
. 2021
;48
(1
):10
–8
. 25.
Mello
SS
, Flowers
BM
, Mazur
PK
, Lee
JJ
, Müller
F
, Denny
SK
, et al. Multifaceted role for p53 in pancreatic cancer suppression
. Proc Natl Acad Sci U S A
. 2023
;120
(10
):e2211937120
. 26.
Qian
Y
, Gong
Y
, Fan
Z
, Luo
G
, Huang
Q
, Deng
S
, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
. J Hematol Oncol
. 2020
;13
(1
):130
. 27.
Casolino
R
, Paiella
S
, Azzolina
D
, Beer
PA
, Corbo
V
, Lorenzoni
G
, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis
. J Clin Oncol
. 2021
;39
(23
):2617
–31
. 28.
Aguirre
AJ
, Nowak
JA
, Camarda
ND
, Moffitt
RA
, Ghazani
AA
, Hazar-Rethinam
M
, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
. Cancer Discov
. 2018
;8
(9
):1096
–111
. 29.
Pilarski
R
. The role of BRCA testing in hereditary pancreatic and prostate cancer families
. Am Soc Clin Oncol Educ Book
. 2019
;39
:79
–86
. 30.
Conroy
T
, Pfeiffer
P
, Vilgrain
V
, Lamarca
A
, Seufferlein
T
, O’Reilly
EM
, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
. Ann Oncol
. 2023
;34
(11
):987
–1002
. 31.
Kindler
HL
, Hammel
P
, Reni
M
, Van Cutsem
E
, Macarulla
T
, Hall
MJ
, et al. Overall survival results from the POLO trial: a phase III study of active maintenance Olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer
. J Clin Oncol
. 2022
;40
(34
):3929
–39
. 32.
Miao
R
, Blue
K
, Sommerer
K
, Shah
A
, Bottiglieri
S
, Del Cueto
A
, et al. PARP inhibitors in pancreatic cancer with homologous recombination repair gene mutations: a single-institution experience
. Cancers (Basel)
. 2024
;16
(20
):3447
. 33.
Crowley
F
, Park
W
, O’Reilly
EM
. Targeting DNA damage repair pathways in pancreas cancer
. Cancer Metastasis Rev
. 2021
;40
(3
):891
–908
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
